Navigation Links
Nile Therapeutics Reports 2010 Second Quarter Financial Results
Date:8/16/2010

SAN MATEO, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.

Financial ResultsFor the three months ended June 30, 2010, Nile reported a net loss of approximately $1.5 million, or $0.05 per share, compared to a net loss of approximately $2.5 million, or $0.10 per share, during the second quarter of 2009. Weighted-average shares outstanding for the second quarter were 32.3 million.

Net cash used in operating activities in the second quarter of 2010 was approximately $1.0 million; net cash provided by financing activities was approximately $4.5 million; and net cash increase in the second quarter of 2010 was approximately $3.6 million. As of June 30, 2010, Nile had cash and cash equivalents of approximately $5.6 million compared to approximately $3.2 million as of December 31, 2009.

Update on CD-NPDuring June 2010, Nile completed enrolling a placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure ("ADHF") in the United States, Germany and Israel. In total, 77 patients were randomized into four doses of CD-NP (1.25, 2.5, 3.75 and 5 ng/kg/min) vs. placebo. The last patient visit occurred at the end of July and final results from the study are expected in the fourth quarter of 2010. Also in the fourth quarter of 2010, Nile plans to submit to the FDA for review and discussion, the clinical protocol for a double-blind, placebo controlled Phase IIb study of CD-NP in ADHF patients.

About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developin
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 ... partnering event for buyers and sellers of high-value chemistry, ... annual conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 ... companies will take part in the conference, which includes ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ... states Dr Barnes. She goes on to state "my wish list ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Mich., Oct. 29 Perrigo Company (Nasdaq: PRGO;TASE) today ... dividend of $0.0625 per share, payable on December 15, ... The new quarterly dividend of $0.0625 per share ... paid in the last four quarters. , Perrigo ...
... HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- ... ), the global specialty biopharmaceutical company, announced today that it ... treatments, INTUNIV (TM) (guanfacine) Extended Release Tablets, ... and Daytrana ®( ) (methylphenidate transdermal system) ...
Cached Medicine Technology:Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 4Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 6Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 7Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 8Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 9
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... March 23 (HealthDay News) -- A new study helps ... drug therapy. Researchers at the Massachusetts General Hospital ... non-small cell lung cancer, the leading cause of cancer ... with resistance. They also confirmed resistance-related genetic changes ...
... Concordia University have pioneered a computer-based method to detect ... that may open a window on the brain,s electrical ... Detection of Epileptic Seizures," presented at the annual meeting ... the very successful application of this new seizure-detection method. ...
... in French . The human brain loses 5 ... 90 years old. While some cells are lost, the brain is ... results of her most recent clinical study published today in the ... Sylvie Belleville, PhD in neuropsychology, the principal author of this study ...
... will convene in Chicago this week to present new ... detect, treat, prevent and cure osteoarthritis (OA), which affects ... the Segal North American Osteoarthritis Workshop (SNOW) on March ... as those that follow joint trauma, obesity and the ...
... who take statin drugs commonly used to lower cholesterol ... their cancer return than patients who do not take ... March issue of the International Journal of Radiation OncologyBiologyPhysics, ... Oncology (ASTRO). , In the study, 1,681 men with ...
... March 22 (HealthDay News) -- Trauma injury patients who arrive ... no more likely to die than those who arrive on ... contrast with previous research that said patients with health emergencies ... they arrive at the hospital at night or on weekends. ...
Cached Medicine News:Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:New way to detect epileptic seizures 2Health News:Subjects at risk of Alzheimer's may now be able to delay the onset of their first symptoms 2Health News:Researchers explore new treatments to end OA 2Health News:Trauma Patients Seem More Likely to Survive on Weekends 2
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
... Calibration kit for convenient pH catheter calibration., ... to any procedure. The Alpine Calibration kit ... distilled water for your convenience. Simply cut ... your catheters to soak. No measuring or pouring! ...
Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
Bravo pH capsule with delivery system....
Medicine Products: